Cepharanthine inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing expression of vascular endothelial growth factor and interleukin-8

International Journal of Oncology

Volumn 35, Issue 5, 2009, Pages 1025-1035

  Harada, Koji ^a   Ferdous, Tarannum ^b   Itashiki, Yasutaka ^a   Takii, Michiyo ^a   Mano, Takamichi ^a   Mori, Yoshihide ^a   Ueyama, Yoshiya ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Antiangiogenesis; Cepharanthine; IL 8; NF B; VEGF

Indexed keywords

CEPHARANTHINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; GENE ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; MOUTH CARCINOMA; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SQUAMOUS CELL CARCINOMA; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZYLISOQUINOLINES; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-8; MICE; MICE, NUDE; MOUTH NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70449563093     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000417     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Inagi K, Takahashi H, Okamoto M, Nakayama M, Makoshi T and Nagai H: Treatment effects in patients with squamous cell carcinoma of the oral cavity. Acta Otolaryngol 122 (Suppl 547): 25-29, 2002. (Pubitemid 34913460)
3. Shingaki S, Takada M, Sasai K, Bibi R, Kobayashi T, Nomura T and Saito C: Impact of lymph node metastasis on the pattern of failure and survival in oral carcinomas. Am J Surg 185: 278-284, 2003. (Pubitemid 36298898)
4. Tomita M, Fujitani K and Aoyagi Y: Synthesis of dl-cepharanthine. Tetrahedron Lett 13: 1201-1206, 1967.
5. Saito R, Tsuchiya S, Ishizuka T, Fueki N, Ezawa K, Minato K, Nakano H, Takise A, Kurihara M and Fueki R: Clinical effects of cepharanthine (Ceph.) on leukopenia by chemotherapy in lung cancer patients. J Jpn Soc Cancer Ther 24: 4587-4593, 1989. (Pubitemid 20081480)
6. Ono M: Antitumor effect of cepharanthine: activation of regional lymph node lymphocytes by intratumoral administration. Clin Immunol 19: 1061-1064, 1987.
7. Morioka S, Ono M, Tanaka N and Orita K: Synergistic activation of rat alveolar macrophages by cepharanthine and OK-432. Jpn J Cancer Chemother 12: 1407-1407, 1985. (Pubitemid 17214974)
8. Asaumi J, Kawasaki S, Nishikawa K, Kuroda M and Hiraki Y: Effects of hyperthermia and cepharanthine on adriamycin accumulation with change in extracellular pH. Int J Hyperthermia 11: 27-35, 1995.
9. Nishikawa K, Asaumi J, Kawasaki S, Kuroda M, Takeda Y and Hiraki Y: Influence of cepharanthine on the intracelluar accumulation of adriamycin in normal liver cells and spleen cells of mice in vitro and in vivo. Anticancer Res 17: 3617-3622, 1997. (Pubitemid 27522335)
10. Hotta T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Tsunoda T, Tamai M, Noguchi K, Mizobata S, Arii K and Terasawa H: Modulation of multidrug resistance by cepharanthine in fresh human gastrointestinal tumor cells. Oncology 54: 153-157, 1997. (Pubitemid 27101764)
11. Hotta T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Tsunoda T, Noguchi K, Mizobata S and Terasawa H: Synergistic effects of tamoxifen and cepharanthinee for circumventing the multidrug resistance. Cancer Lett 107: 117-123, 1996. (Pubitemid 26370866)
12. Furusawa S, Wu J, Fujimura T, Nakano S, Nemoto S, Takayanagi M, Sasaki K and Takayanagi Y: Cepharanthinee inhibits proliferation of cancer cells by inducing apoptosis. Methods Find Exp Clin Pharmacol 20: 87-89, 1998. (Pubitemid 28210504)
13. Harada K, Bando T, Yoshida H and Sato M: Characteristics of antitumour activity of cepharanthin against a human adenosquamous cell carcinoma cell line. Oral Oncol 37: 643-651, 2001. (Pubitemid 32925199)
14. Kip1. Anticancer Res 23: 1441-1448, 2003.
15. Williams JK, Carlson GW, Cohen C, Derose PB, Hunter S and Jurkiewicz MJ: Tumor angiogenesis as a prognostic factor in oral cavity tumors. Am J Surg 168: 373-380, 1994. (Pubitemid 24345677)
16. Leung DW, Cachianes G, Kuang WH, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989. (Pubitemid 20066716)
17. Guo D, Jia Q, Song HY, Warren RS and Donner DB: Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 270: 6729-6733, 1995.
18. Smith BD, Smith GL, Carter D, Sasaki CT and Haffty BG: Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 18: 2046-2052, 2000. (Pubitemid 30324357)
19. Maeda T, Matsumura S, Hiranuma H, Jikko A, Furukawa S, Ishida T and Fuchihata H: Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression and p53 gene status. J Clin Pathol 51: 771-775, 1998. (Pubitemid 28480335)
20. Strieter RM, Kunkel SL, Elner VM, Martonyi CL, Koch AE, Polverini PJ and Elner SG: Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol 141: 1279-1284, 1992. (Pubitemid 23002612)
21. Hu DE, Hori Y and Fan TP: Interleukin-8 stimulates angiogenesis in rats. Inflammation 17: 135-143, 1993.
22. Huang S, Robinson JB, Deguzman A, Bucana CD and Fidler IJ: Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60: 5334-5339, 2000. (Pubitemid 30761236)
23. Okamoto M, Ono M and Baba M: Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. AIDS Res Hum Retroviruses 14: 1239-1245, 1998. (Pubitemid 28488934)
24. Kip1 induces growth arrest and apoptosis in an oral cancer cell line. Oral Oncol 38: 730-736, 2002.
25. Schor AM, Schor SL and Allen TD: Effects of culture conditions on the proliferation, morphology and migration of bovine aortic endothelial cells. J Cell Sci 62: 267-285, 1983.
26. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated calorimetric assay: Assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987. (Pubitemid 17027905)
27. Renard P, Ernest I, Houbion A, Art M, Le Calvez H, Raes M and Remacle J: Development of a sensitive multi-well colorimetric assay for active NF-kappaB. Nucleic Acids Res 29: E21, 2001.
28. Pazouki S, Chisholm DM, Adi MM, Carmichael G, Farquharson M, Ogden GR, Schor SL and Schor AM: The association between tumour progression and vascularity in the oral mucosa. J Pathol 183: 39-43, 1997. (Pubitemid 27368524)
29. Tamatani T, Azuma M, Aota K, Yamashita T, Bando T and Sato M: Enhanced IkappaB kinase activity is responsible for the augmented activity of NF-kappaB in human head and neck carcinoma cells. Cancer Lett 171: 165-172, 2001. (Pubitemid 32772803)
30. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
31. Weinstat-Saslow D and Steeg PS: Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 8: 401-407, 1994. (Pubitemid 24155952)
32. Li C, Shintani S, Terakado N, Klosek SK, Ishikawa T, Nakashiro K and Hamakawa H: Microvessel density and expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived endothelial growth factor in oral squamous cell carcinomas. Int J Oral Maxillofac Surg 34: 559-565, 2005. (Pubitemid 40790355)
33. Xie K: Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12: 375-391, 2001.
34. Gokhale AS, Haddad RI, Cavacini LA, Wirth L, Weeks L, Hallar M, Faucher J and Posner MR: Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol 41: 70-76, 2005. (Pubitemid 39647122)
35. Watanabe H, Iwase M, Ohashi M and Nagumo M: Role of interleukin-8 secreted from human oral squamous cell carcinoma cell lines. Oral Oncol 38: 670-679, 2002. (Pubitemid 34880105)
36. Bancroft CC, Chen Z, Dong G, Sunwoo JB, Yeh N, Park C and Van Waes C: Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 7: 435-442, 2001. (Pubitemid 32183050)
37. Yoshida A, Yoshida S, Khalil AK, Ishibashi T and Inomata H: Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci 39: 1097-1106, 1998. (Pubitemid 28247343)
38. Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ: Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197, 2001. (Pubitemid 32762193)
39. Huang S, DeGuzman A, Bucana CD and Fidler IJ: Nuclear factor-B activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 6: 2573-2581, 2000. (Pubitemid 30399230)
40. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, Jackson C and Van Waes C: Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99: 538-548, 2002. (Pubitemid 34461606)
41. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA and Narayanan R: Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci USA 90: 9901-9905, 1993. (Pubitemid 23328218)
42. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, Siebenlist U and Van Waes C: Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 59: 3468-3474, 1999. (Pubitemid 29334510)
43. Wang W, Abbruzzese JL, Evans DB and Chiao PJ: Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated relA. Oncogene 18: 4554-4563, 1999. (Pubitemid 29405887)
44. Bond M, Fabunmi RP, Baker AH and Newby AC: Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappaB. FEBS Lett 435: 29-34, 1998. (Pubitemid 28432009)